Search the Newsreel

Analysts Conflicted on These NA Names: Bicara Therapeutics Inc. (BCAX), CoreWeave (CRWV) and Cardinal Infrastructure Group, Inc. (CDNL)

The article summarizes recent analyst ratings for Bicara Therapeutics Inc. (BCAX), CoreWeave (CRWV), and Cardinal Infrastructure Group, Inc. (CDNL). Goldman Sachs maintained a Hold rating for Bicara Therapeutics, while Piper Sandler reiterated a Buy rating for CoreWeave, and Stifel Nicolaus maintained a Buy rating …

Cardinal Health sees more runway in fragmented at-home medical supplies market

Cardinal Health's acquisitions of Strive Medical and AdaptHealth's diabetes business are projected to add two percentage points of growth to its Other segment in fiscal year 2027, strengthening its position in the at-home medical supplies and diabetes markets. CEO Jason Hollar highlighted the fragmented …

Prévisions sur l’action Pernod Ricard : le test de la résistance pourrait définir la prochaine tendance

Cardinal Health: Q4 Presents Positive Signal For The Company's Long-Term Growth (NYSE:CAH)

CDNL INVESTOR ALERT: Investigation of Cardinal Infrastructure Group Inc. Announced by Holzer & Holzer, LLC

Holzer & Holzer, LLC has announced an investigation into Cardinal Infrastructure Group Inc. (NASDAQ: CDNL) regarding potential violations of federal securities laws. This investigation follows Cardinal's Q2 2026 financial results, which showed a significant drop in Adjusted EBITDA margin and a subsequent decrease in …

Cardiol Therapeutics GAAP EPS of -C$0.05

* Cardiol Therapeutics press release [https://seekingalpha.com/filing/309942772] (CRDL:CA [https://seekingalpha.com/symbol/CRDL:CA]): Q2 GAAP EPS of -C$0.05. MORE ON CARDIOL THERAPEUTICS * Historical earnings data for Cardiol Therapeutics [https://seekingalpha.com/symbol/CRDL:CA/earnings] * Financial information for Cardiol Therapeutics [https://seekingalpha.com/symbol/CRDL:CA/income-statement]

Ackman adds Netflix, Visa and Mastercard in portfolio revamp

Investing.com -- Bill Ackman disclosed six new portfolio holdings on Thursday, including Netflix, Visa, and Mastercard, representing his largest portfolio restructuring in several years. The billionaire investor said he began purchasing the shares during the second quarter for his investment funds, including Pershing Square …

JPMorgan Adjusts Cardinal Health Price Target to $260 From $215, Maintains Neutral Rating

JPMorgan has raised its price target for Cardinal Health (CAH) to $260 from $215, while maintaining a Neutral rating on the stock. This adjustment comes amidst several other analyst updates for Cardinal Health, with firms like Evercore ISI, TD Cowen, and Deutsche Bank also …

CPI Card Group (PMTS) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 9:00 a.m. ET CALL PARTICIPANTS Head of Investor Relations - Davis Barker President and Chief Executive Officer - John Lowe Chief Financial Officer - Terra Grantham Full Conference Call Transcript Operator: Welcome to …

Evercore ISI Adjusts Cardinal Health PT to $270 From $265, Maintains Outperform Rating

Evercore ISI has raised its price target for Cardinal Health (CAH) to $270 from $265, while reiterating an Outperform rating on the stock. This adjustment reflects a continued positive outlook from the analyst firm on the pharmaceutical distributor. The news highlights recent analyst activity …

Ackman unveils six new investments including Netflix, Visa, Mastercard in biggest portfolio overhaul in years

By Svea Herbst-Bayliss NEW YORK, Aug 13 (Reuters) - Bill Ackman unveiled six new holdings including Netflix, Visa and Mastercard, marking the billionaire investor's biggest portfolio overhaul in years. Ackman said on Thursday he acquired shares ‌starting in the second quarter that will be …

Deutsche Bank Adjusts Cardinal Health Price Target to $261 From $223, Maintains Hold Rating

Deutsche Bank has updated its price target for Cardinal Health (CAH), increasing it to $261 from the previous $223, while keeping a "Hold" rating on the stock. This adjustment reflects new analyst valuations for the pharmaceutical distributor. The article also lists other recent analyst …

Cardinal Health’s Q4 Earnings Explained: A Revenue Miss, a Profit Beat

BioCardia Inc (BCDA) (Q2 2026) Earnings Call Highlights: Regulatory Wins in Japan and US ...

BioCardia Inc. (BCDA) reported its Q2 2026 earnings, highlighting significant regulatory progress in Japan and the US for its cardiac cell therapy and Helix delivery catheter. The company received positive feedback from both the PMDA and FDA, supporting its path to market approval, and …

BioCardia Q2 loss narrows 67.5% YoY; regulatory milestones advance

BioCardia Inc. reported a significant narrowing of its Q2 2026 net loss to $1.6 million, an improvement of 21.3% year-over-year, beating EPS estimates by 27.78%. The company also announced key regulatory advancements, including PMDA support for a Q4 2026 CardiAMP submission in Japan and …

Ackman's Pershing Square Inc. Q2 earnings beat; highlights Mastercard and Visa stakes (PS:NYSE)

Earnings call transcript: BioCardia posts q2 2026 loss beat, shares rise after hours

BioCardia (BCDA) reported a smaller-than-expected Q2 2026 loss of $0.13 per share, beating analyst estimates of $0.18, and its shares rose in after-hours trading. The company highlighted significant regulatory progress, including support from Japan's PMDA for a Shonin submission for CardiAMP cell therapy and …

Cardinal Health Inc. stock underperforms Wednesday when compared to competitors

Cardinal Health Inc. (CAH) stock declined by 2.54% on Wednesday, closing at $234.16. This underperformance occurred on a mixed trading day where the S&P 500 Index rose, and the Dow Jones Industrial Average slightly fell. The stock's drop ended a two-day winning streak.

Is BioCardia Inc (BCDA) Facing Financial Challenges After Q2 Ear

Cardiol Therapeutics (CRDL) posts Q2 2026 loss but extends cash runway to Q4 2027

BioCardia, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

BRIEF-BioCardia, Inc. Q2 Net Income USD -1.613 Million

BioCardia, Inc. reported a Q2 net income of USD -1.613 million. The article from Reuters provides a brief update on the company's financial performance. Full access to this and other news sources is available through a TradingView subscription.

BioCardia reports Q2 2026 net loss narrows to $1.6M; cash $4.1M with runway into 2027

BioCardia (BCDA) reported a net loss of $1.6 million for Q2 2026, a reduction from $2.0 million in the prior year, and holds $4.1 million in cash, projecting a runway into 2027. The company is actively pursuing regulatory approvals in Japan and the US …

BioCardia Reports Second Quarter 2026 Business Highlights and Financial Results

BioCardia, Inc. reported its second-quarter 2026 financial results, highlighting significant progress in regulatory discussions with agencies in Japan and the U.S. The company achieved important milestones including PMDA support for CardiAMP Cell Therapy submission in Japan, FDA acknowledgement that the CardiAMP HF II trial …

Cardiol Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Cardinal Health (CAH) Stock Looks About Right On Earnings But Stretched On Broader Checks

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. After a very strong multi year run, Cardinal Health stock is now being judged by a low overall value score and fresh questions about …

What’s Next For Cardiol Therapeutics (TSX:CRDL) Research?

Cardiol Therapeutics (TSX:CRDL) is a clinical-stage life sciences company focused on developing therapies for cardiovascular conditions, with its research strategy centered on addressing unmet therapeutic needs in this area. The company's future hinges on clinical execution, regulatory developments, and the quality of its trial …

Cardinal Health Earnings: Can Perfection Get Priced In Twice?

Cardinal Health (CAH) saw its stock hit a new all-time high despite mixed Q4 fiscal year results, including a revenue miss and a decline in its Global Medical Products and Distribution unit. The company's growth is being driven by its high-margin cell-and-gene-therapy logistics business, …

Cardinal Infrastructure Group Reports Robust Q2 2026 Financial Growth in 10-Q Filing

Cardinal Infrastructure Group Inc. (NASDAQ:CDNL) submitted its Q2 2026 Form 10-Q report, revealing significant financial growth. The company reported a near doubling of revenue to $394.4 million for the first half of 2026, with total assets exceeding $1 billion. Despite a decrease in net …

Millions of consumers could get £70 each after Mastercard lawsuit

Customers can expect payouts of up to £70 as part of a landmark group legal case against Mastercard next year after it settled outside court for £200m. You can't make claims just yet, but here's a rundown of who is eligible, how the process …

Broker Revenue Forecasts For Cardinal Infrastructure Group Inc. (NASDAQ:CDNL) Are Surging Higher

Keurig Dr Pepper Adds Cardinal Health CFO Aaron Alt to Board

Keurig Dr Pepper has appointed Cardinal Health CFO Aaron Alt to its board of directors, effective August 14, 2026. Alt's extensive experience in finance and corporate transformation, including serving as CFO for three public companies, will be crucial as KDP prepares to separate into …

Cardiff Loss Narrows In Q2; Directs Resources To Phase 3 For Onvansertib In Q1 '27

(RTTNews) - Cardiff Oncology, Inc. (CRDF) a clinical-stage oncology company, reported second quarter results, reflecting a narrower loss primarily driven by lower operating expenses. The company in particular noted reduced Research and Development (R&D) expenses following the completion of clinical trials and lesser preclinical …

Wells Fargo & Company Forecasts Strong Price Appreciation for Cardinal Health (NYSE:CAH) Stock

Mastercard (MA) Starts A Cross Border Stablecoin Payments Pilot

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Mastercard (NYSE: MA) and Borderless.xyz announced a pilot collaboration to advance trusted cross-border stablecoin payments using Mastercard Crypto Credential standards. The initiative applies …

Mizuho raises Cardinal Health stock price target to $250 on earnings